Pharmaniaga Berhad, an investment holding company, (7081) Fair Value & Analysis
Healthcare · MY · Market cap 1.6B MYR
Fair value as of: Jul 12, 2026
From 15 valuation models · updated 29 days ago
Share price −4.9% over the past month.
Below-average quality, and screening another 48% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.8075 MYR). The favourable scenario is already priced in.
- Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (0.3825 MYR to 0.8075 MYR) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 0.5894 MYR – 3.36 MYR · fair‑value band 0.3825 MYR – 0.8075 MYR · the 1.17 MYR price screens above the 0.6035 MYR fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Pharmaniaga Berhad, an investment holding company, (7081) currently trades at 1.17 MYR, while our model-based Fair Value estimate is 0.6035 MYR, implying the stock looks roughly 48.4% overvalued today. The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Pharmaniaga Berhad, an investment holding company, generated revenue of 4.1B MYR at a net margin of 1.2%. Revenue grew 11.7% year over year. It earns a return on equity of 28.4%. Net debt stands at 709M MYR. Fundamentals as of Jul 12, 2026
Our scenario range runs from 0.3825 MYR (bear case) to 0.8075 MYR (bull case); at 1.17 MYR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 85% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -48%, 7081 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Multiples (0.8100 MYR) versus Asset-Based (0.2200 MYR). Highest evidence: Residual Income (76).
Notify me when 7081 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 28 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through Logistics and Distribution, Manufacturing, and Indonesia segments.
Full company description
Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through Logistics and Distribution, Manufacturing, and Indonesia segments. It is involved in manufacturing, distribution, and marketing of pharmaceutical and medical products, such as generic drugs and over-the-counter medicines; supply and installation of medical and hospital equipment; and research and development of pharmaceutical products. The company also produces and distributes food supplements. In addition, it distributes and trades diagnostic products; and develops OLIN digital platform, an integrated digital platform for ordering, inventory, billing, and sales operations. Further, the company provides logistics services and primary care products for acute diseases and specialty care products for serious and chronic diseases. Pharmaniaga Berhad was founded in 1994 and is based in Shah Alam, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharmaniaga Berhad, an investment holding company, reported revenue of 3.9B MYR in FY2025 versus 4.8B MYR in FY2021, a compound −5.0%/yr. Reported net income was 48.5M MYR in FY2025, compounding −27.1%/yr from FY2021.
7081 screens 48% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare Pharmaniaga Berhad, an investment holding company, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharmaniaga Berhad, an investment holding company, (7081) overvalued or undervalued?
What is the fair value of 7081?
What is the quality score of 7081?
What is the revenue of Pharmaniaga Berhad, an investment holding company, (7081)?
What is the net profit margin of 7081?
Does Pharmaniaga Berhad, an investment holding company, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pharmaniaga Berhad, an investment holding company, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.